Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 5/20 | 0.64 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | GRM5 | P41594 | 1/20 | 0.53 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.51 |
| ▸ | FEN1 | P39748 | 1/20 | 0.51 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
| ▸ | CAMK2D | Q13557 | 4/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | FYN | P06241 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14457462 | 0.90 | HPGDS (0.60) | HPGDSATMGRM5RAB9ASMN1; SMN2 | |
| SCHEMBL38227 | 0.78 | HPGDS (1.00) | HPGDSNPC1RAB9ASMN1; SMN2EPHX2 | |
| SCHEMBL13876383 | 0.78 | ATM (0.53) | ATMGRM5ERCC1FEN1ERCC4 | |
| SCHEMBL13450864 | 0.77 | EPHX2 (0.69) | GRM5NPC1RAB9ASMN1; SMN2NAMPT | |
| SCHEMBL13876393 | 0.76 | GRM5 (0.56) | HPGDSGRM5NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL13876810 | 0.76 | HPGD (0.56) | GRM5NPC1RAB9ASMN1; SMN2NAMPT | |
| SCHEMBL14974164 | 0.76 | HPGDS (1.00) | HPGDSNPC1RAB9ASMN1; SMN2EPHX2 | |
| SCHEMBL13876399 | 0.76 | GRM5 (0.56) | HPGDSGRM5FEN1NPC1RAB9A | |
| SCHEMBL38498 | 0.76 | HPGDS (0.63) | HPGDSNPC1RAB9ASMN1; SMN2CAMK2D | |
| SCHEMBL13876401 | 0.76 | NPC1 (0.55) | HPGDSGRM5NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099184-A1 | Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-16 | — | — | US | disclosed |
| US-20090099184-A1 | Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-16 | — | — | US | disclosed |
| WO-2007098352-A2 | SUBSTITUTED PYRIDINEAMIDE COMPOUNDS USEFUL AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099184-A1 | Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors | EPHX1, EPHX2, NCEH1 | HPGDS 29/4885ATM 4659/4885GRM5 3574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.